Archives for September 24, 2007

← 2007

US firm launches online patient recruitment tool

By  Emilie Reymond

Californian marketing company BlueLithium has launched a new web-based solution to help pharma companies overcome the challenges of recruiting patients for clinical trials.

Epinephrine CFC inhalers on the way out

By  Katrina Megget

The US Food and Drug Administration (FDA) has proposed plans to phase out chlorofluorocarbons (CFCs) in metered dose inhalers that contain epinephrine, but the decision could spell the end for some asthma treatments.

Weekly Comment

Viracept contaminant could be widespread, FDA says

By  Anna Lewcock

Following the recent news that pharma heavyweight Pfizer has also been struck by contamination of its HIV drug Viracept (nelfinavir), in-PharmaTechnologist.com spoke to the US Food and Drug Administration (FDA) to find out how far reaching the...

Biogen bags two discovery partnerships

By  Emilie Reymond

Biogen Idec has bagged two new partnerships in the past week which will see it involved in the search for new drugs for central nervous system (CNS) and inflammatory ailments.

Allergies not a patch on DBV

By  Katrina Megget

DBV Technologies is advancing into the realm of allergy treatment and vaccine delivery using its Viaskin technology, which has already proved successful as an allergy diagnostic.

Wyatt lights up protein aggregation

By  Dr Matt Wilkinson

Wyatt Technologies has launched a new instrument that automates protein aggregation measurement for use in all areas of the pharmaceutical industry from drug development to quality control (QC).

BMS buys biologics partner, strengthens oncology

By  Dr Matt Wilkinson

Bristol-Myers Squibb (BMS) will pay up to $490m (€348m) for Adnexus Therapeutics, as it continues its transformation into a biopharmaceutical company and strengthens its oncology pipeline.

Tougher food import laws proposed

By  Charlotte Eyre

A bill proposing stricter import regulations has been presented to Congress, as fears over imported food products show no sign of diminishing.